Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT02555813 |
Date of registration:
|
18/09/2015 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Treatment of Pancreatic Cancer With Abraxane
|
Scientific title:
|
Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients |
Date of first enrolment:
|
May 8, 2015 |
Target sample size:
|
317 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT02555813 |
Study type:
|
Observational |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
Austria
| | | | | | | |
Contacts
|
Name:
|
Guenter Voraberger, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Celgene Austria |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Metastatic pancreatic carcinoma
2. Age > 18 years
3. Signed Informed Consent
4. Normal hepatic, renal and Bone Marrow functions
Exclusion Criteria:
1. Pregnant and lactating females 2. Previous treatment for metastatic pancreatic disease
3. Known hypersensitivity to nab-paclitaxel 4. Neutrophils < 1,5 x 10^9/L
-
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Metastatic Pancreatic Cancer
|
Intervention(s)
|
Drug: Abraxane
|
Drug: Gemcitabine
|
Primary Outcome(s)
|
Number of participants with adverse events
[Time Frame: Up to 5 years]
|
Secondary Outcome(s)
|
Best Overall Response
[Time Frame: Up to 5 years]
|
Secondary ID(s)
|
ABI-007-PANC-006
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|